Evaluation of Pro root-MTA and Retro root-MTA in partial pulpotomy of human dental healthy pulp
Phase 2
- Conditions
- Vital pulp therapy.Infection diseaseIA49.1
- Registration Number
- IRCT2016020420004N3
- Lead Sponsor
- Vice challenger of research,Islamic Azad Dental University of Tehran
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
age between18-32 years old; erupted third molar; closed apex; caries free; normal sign to vitality tests. Exclusion criteria: external or internal resorptin; peri apical lesion.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulp health(Post Operative sensitivity and pain ). Timepoint: After treatment,1 week later and before extraction. Method of measurement: Vitality test,Cold test and EPT.;Signs of periapical pathology. Timepoint: Radiographs are taken before intervention and extraction. Method of measurement: PA Radiography.
- Secondary Outcome Measures
Name Time Method Dentin barrier formation. Timepoint: Eight weeks after beginning treatment. Method of measurement: Histological examination after extraction.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the biomolecular pathways involved in Pro root-MTA and Retro root-MTA efficacy for partial pulpotomy in healthy dental pulp?
How does Pro root-MTA compare to Retro root-MTA in clinical outcomes for partial pulpotomy in vital pulp therapy?
Which inflammatory biomarkers correlate with pulpal healing success in IRCT2016020420004N3 phase II MTA trials?
What adverse events are associated with Pro root-MTA and Retro root-MTA use in phase II partial pulpotomy trials?
Are there alternative pulp capping materials or combination therapies that enhance outcomes compared to MTA in vital pulp therapy?